SARS-CoV-2-derived peptide epitopes presented by HLA class II and recognized by T-cell receptors (SARS-CoV-2 HLA-II-peptide-TCR complex)

SARS-CoV-2-derived peptide epitopes presented by HLA class II molecules are fundamental components of the adaptive immune system's recognition of the SARS-CoV-2 virus. These epitopes consist of specific peptide fragments derived from viral proteins, such as Spike, Nucleocapsid, and Membrane proteins, which are processed and displayed on the surface of professional antigen-presenting cells (Grifoni et al., 2020, Cell). When these peptide-HLA complexes are recognized by the T-cell receptors (TCRs) of CD4+ T cells, they initiate a cascade of immune signaling essential for viral clearance (Mateus et al., 2020, Science). This interaction is a primary target for vaccine development, as vaccines like BNT162b2 and mRNA-1273 are designed to induce the presentation of these epitopes to generate robust T-cell memory (Tarke et al., 2021, Cell Reports Medicine). Furthermore, the breadth and specificity of the TCR repertoire for these epitopes determine the effectiveness of the immune response and the potential for cross-reactivity with other coronaviruses (Saini et al., 2021, Science Immunology). Monitoring these interactions is crucial for evaluating vaccine efficacy and understanding the impact of viral variants on T-cell immunity (Dan et al., 2021, Science). Therapeutic interventions also explore the use of these epitopes in peptide-based vaccines or T-cell therapies to enhance protection in immunocompromised individuals.

Other names

SARS-CoV-2 CD4+ T-cell epitopesHLA class II-restricted SARS-CoV-2 antigensSARS-CoV-2 pMHC-II complexesSARS-CoV-2 T-helper cell epitopes

Activation of CD4+ T-helper cells via TCR recognition of HLA-II restricted viral peptides, leading to B-cell stimulation and cytokine-mediated coordination of the adaptive immune response.